Verified employee & interview reviews

Sun Pharma Reviews

Mumbai, Maharashtra

—/ 5

0 reviews

Sun Pharmaceutical Industries Limited, widely known as Sun Pharma, is a prominent Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. Established in 1983 by Dilip Shanghvi in Calcutta, West Bengal, the company began its operations with just five psychiatry products and a two-person marketing team. Over the decades, through strategic organic growth and aggressive international acquisitions, Sun Pharma has evolved into the largest pharmaceutical company in India and ranks as the fourth-largest specialty generic pharmaceutical company globally. The core operations of Sun Pharma revolve around the development, manufacturing, and marketing of a diversified portfolio of pharmaceutical products. This includes generic and branded generic formulations, active pharmaceutical ingredients (APIs), specialty complex products, over-the-counter (OTC) remedies, antiretrovirals (ARVs), and intermediates. The company provides these medications across multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Sun Pharma's vast product basket addresses chronic and acute conditions across numerous therapeutic segments, notably neuropsychiatry, cardiology, diabetology, gastroenterology, neurology, ophthalmology, nephrology, urology, dermatology, oncology, and respiratory health. Sun Pharma boasts an expansive global manufacturing and distribution footprint. The company operates 43 manufacturing sites spread across five continents, including facilities in India, the United States, parts of Asia, Africa, Australia, and Europe. It distributes high-quality, affordable medicines to healthcare professionals and patients in more than 100 countries worldwide. International markets account for approximately 70% of the company's total revenue, with the United States and India standing as its largest commercial regions. In the U.S. market specifically, which contributes roughly one-third of global turnover, Sun Pharma is a leading specialty generic player and ranks second in generic dermatology by prescriptions. Innovation remains a cornerstone of Sun Pharma's corporate strategy. The company allocates approximately 6% to 8% of its annual global revenues toward Research and Development (R&D). Its scientific endeavors are driven by an international team of around 2,900 R&D personnel and scientists working across multiple specialized innovation hubs globally. Financially, Sun Pharma is a publicly traded entity listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). For the fiscal year 2025, the company reported an annual consolidated revenue of INR 52,578 crore (approximately US$ 5.5 billion), an operating income of INR 15,271 crore, and a net income of INR 11,984 crore. Under the ongoing leadership of Founder and Managing Director Dilip Shanghvi and CEO Kirti Wardhaman Ganorkar, the company continues its expansion, highlighted by recent high-profile acquisitions including Taro Pharmaceuticals, Concert Pharmaceuticals, Checkpoint Therapeutics, and Organon & Co.